7/24/2023 0 Comments Metformin er 500 mg![]() ![]() Standard metformin suffers from the limitations of having to be administered two or three times a day and with the attendant risk of triggering gastrointestinal symptoms affecting 25% of patients making dose optimization problematic. Metformin is recommended in International Guidelines as first line therapy due to its favourable profile on metabolic indices of glucose, lipid and weight control as well as offering protection from life threatening complications and premature mortality. Lifestyle change and the use of pharmaceutical therapies are considered pivotal to achieving good control of glycaemia and other cardiovascular risk factors in the expectation of avoiding long-term complications and premature mortality. Its epidemic proportions worldwide, including Brazil, make it a public health issue and the present goal is to implement policies aimed at both its prevention and management. Type 2 Diabetes Mellitus is a chronic and progressive disease which demands intense management from diagnosis and through the various stages of the disease. Patients switched to extended release metformin XR derived the same clinical and metabolic benefits as for standard metformin but with reduced dosage, fewer gastrointestinal side effects and a greater sense of well being and satisfaction on medication. Ghost tablets were reported in the faeces by the majority of the patients (54.1%). A total of 77% of patients were free of gastrointestinal side effects and 83% of patients stated a preference for metformin XR at the end of the study. These effects were achieved with a reduced dose of metformin XR compared to pre-study dosing with standard metformin (1500 mg +/- 402 vs 1861 +/- 711 p = 0.004). At three and six months no changes were reported for any of the cardiovascular risk factors except for lipids where there was a modest rise in plasma triglycerides. ResultsĬomplete data were obtained for 35 of the 61 patients enrolled to the study. Patients on immediate release standard metformin either alone or combined with other oral agents were switched to extended release metformin XR 500 mg tablets and titrated to a maximum dose of 2000 mg/day Measurements to include glucose and lipid control, blood pressure, body weight, waist circumference, C-reactive protein, adverse events and patient satisfaction were recorded at baseline, three and six months. To determine prospectively the efficacy, tolerability and patient satisfaction of an extended release formulation of metformin (metformin XR) in hospital based outpatients with type 2 diabetes mellitus currently treated with standard metformin.
0 Comments
Leave a Reply. |